The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Questcor to Report First Quarter 2012 Earnings and Conduct Conference Call on April 24, 2012

Tuesday, April 10, 2012

Questcor to Report First Quarter 2012 Earnings and Conduct Conference Call on April 24, 201207:00 EDT Tuesday, April 10, 2012ANAHEIM, Calif., April 10, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2012 financial results on Tuesday, April 24, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, April 24, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the first quarter, as well as current corporate developments. Conference call details:Date:   Tuesday, April 24, 2012Time:  4:30 p.m. ET Dial-in (U.S.): 877-354-0215Dial-in (International):         253-237-1173Web cast:  www.questcor.com To access an audio replay of the call:Replay (U.S.):   855-859-2056Replay (International):404-537-3406Replay Passcode:  70200329 About Questcor                                                                                      Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Questcor currently generates substantially all of its net sales from: the treatment of patients with acute exacerbations of multiple sclerosis in adults, the treatment of patients with nephrotic syndrome, and the treatment of patients with infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, and Dermatomyositis (Polymyositis).  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information about Questcor, please visit www.questcor.com.                      SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey, Questcor Pharmaceuticals, Inc., +1-714-786-4210, dbailey@Questcor.com; or Investors, Gregory Gin, +1-646-445-4801, or Doug Sherk, +1-415-568-4887, or Media, Janine McCargo, +1-646-688-0425, of EVC Group